Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Part B Drug Compendia For Off-Label Chemotherapy May Be Updated Annually

Executive Summary

CMS will annually solicit public comment on updating the list of compendia used by Medicare Part B contractors in making local coverage determinations for off-label cancer drugs and biologicals, according to a proposed rule scheduled for July 12 publication in the Federal Register

You may also be interested in...



CMS Will Detail MedCAC Research Role In Response To Industry Concerns

CMS will more fully describe how it intends to use its Medicare Evidence Development and Coverage Advisory Committee to set research priorities, CMS Chief Medical Officer Barry M. Straube said at an April 30 MedCAC meeting in Baltimore

CMS Will Detail MedCAC Research Role In Response To Industry Concerns

CMS will more fully describe how it intends to use its Medicare Evidence Development and Coverage Advisory Committee to set research priorities, CMS Chief Medical Officer Barry M. Straube said at an April 30 MedCAC meeting in Baltimore

CMS modifies anti-cancer compendia rules

CMS slightly modifies the timeline for addition and deletion of compendia approved for use by Medicare Part B contractors in making local coverage decisions for off-label cancer drugs and biologicals from the 2008 proposed physician fee schedule update rule (1"The Pink Sheet" July 9, 2007, p. 13). According to the final rule, CMS will not publish an annual notice for formal requests to update the approved list of compendia, but will annually open a 30-day window on Jan. 15 for submissions. The agency says it expects to post submissions by March 15 on its Web site for a 30-day public notice and comment period...

Related Content

UsernamePublicRestriction

Register

LL009864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel